Evidence map›Paper›PMID 34755663›Full record

ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2021

[Vascular endothelial growth factor promotes cancer stemness of triple-negative breast cancer via MAPK/ERK pathway].

L Wang, L Zhao, L Zhang, X Jing, Y Zhang, S Shao, X Zhao, M Luo

Open access · greenAbstract read
In one paragraph

Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Regulation of VEGF-A expression and VEGF-A-targeted therapy in malignant tumors.Journal of cancer research and clinical oncology · 2024
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

L WangDepartment of Oncology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
L ZhaoDepartment of Oncology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
L ZhangDepartment of Oncology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
X JingDepartment of Oncology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Y ZhangDepartment of Respiratory, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
S ShaoDepartment of Oncology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
X ZhaoDepartment of Oncology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
M LuoDepartment of Hematology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
First Affiliated Hospital of Xi'an Jiaotong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the role of vascular endothelial growth factor (VEGF) in regulating triple-negative breast cancer (TNBC) stem cells and the possible pathways involved in this regulatory mechanism.

methodsThe Oncomine database, UALCAN database and Human Protein Atlas (HPA) database were used to analyze the expression of VEGF in breast cancer and its association with the molecular subtypes and prognosis of breast cancer. Sphere formation assay was carried out to examine the effects of hVEGF

resultsData from the online databases all showed a significant increase of VEGF expression in breast cancer tissues than in the adjacent tissues (

conclusionVEGF promotes cancer stemness of triple-negative breast cancer possibly through the ERK/MAPK pathway.

Indexed as

Triple Negative Breast NeoplasmsVascular Endothelial Growth Factor ACell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansMAP Kinase Signaling SystemNeoplastic Stem CellsVascular Endothelial Growth Factor Acancer stem cellstriple-negative breast cancervascular endothelial growth factor

Identifiers

PMID34755663
PMCPMC8586860
OpenAlexW3211884966

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.